ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript By Sigma Griffin · April 1, 2026 · 1 min read oricsa transcripts Source: seekingalpha.com